Cervical dystonia: Effectiveness of a standardized physical therapy program; study design and protocol of a single blind randomized controlled trial

BMC Neurology

Volumn 13, Issue , 2013, Pages

  van den Dool, Joost ^a,b   Visser, Bart ^b   Koelman, J Hans T M ^c   Engelbert, Raoul H H ^b,c   Tijssen, Marina A J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Amsterdam School of Health Professions   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Activities of daily living; Botulinum toxin; Cervical dystonia; Physical therapy; Quality of life; Spasmodic torticollis

Indexed keywords

BOTULINUM TOXIN;

ADULT; ANXIETY; ARTICLE; CERVICAL DYSTONIA; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DISABILITY; DISEASE SEVERITY; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PHYSIOTHERAPY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RANGE OF MOTION; RATING SCALE; SINGLE BLIND PROCEDURE; STUDY DESIGN;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; ANTI-DYSKINESIA AGENTS; ANXIETY; BOTULINUM TOXINS; COST-BENEFIT ANALYSIS; DEPRESSION; DISABILITY EVALUATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PAIN; PHYSICAL THERAPY MODALITIES; QUALITY OF LIFE; RANGE OF MOTION, ARTICULAR; RESEARCH DESIGN; SINGLE-BLIND METHOD; TORTICOLLIS; TREATMENT OUTCOME;

EID: 84880113430     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-13-85     Document Type: Article

References (48)

1. Fahn S, Marsden CD, Calne DB. Classification and investigation of dystonia. Mov Disord 1987, 2:332-358.
2. Epidemiologic Study of Dystonia in Europe (ESDE) CollaborativeGroup A prevalence study of primary dystonia in eight European countries. J Neurol 2000, 247:787-792. 10.1007/s004150070094, 11127535, Epidemiologic Study of Dystonia in Europe (ESDE) CollaborativeGroup.
3. Lowenstein DH, Aminoff MJ. The clinical course of spasmodic torticollis. Neurology 1988, 38:530-532. 10.1212/WNL.38.4.530, 3352905.
4. Chan J, Brin M, Fahn S. Idiopathic cervical dystonia: clinical characteristics. Mov Disord 1991, 6:119-126. 10.1002/mds.870060206, 2057004.
5. Jankovic J, Leder S, Warner D, et al. Cervical dystonia: clinical findings and associated movement disorders. Neurology 1991, 41:1088-1091. 10.1212/WNL.41.7.1088, 2067638.
6. Kutvonen O, Dastidar P, Nurmikko T. Pain in spasmodic torticollis. Pain 1997, 69:286.
7. Zetterberg L, Lindmark B, Soderlund A, Asenlof P. Self-Perceived non-motor aspects of cervical dystonia and their association with disability. J Rehabil Med 2012, 44:950-954. 10.2340/16501977-1055, 23069793.
8. Cassidy A. Pathophysiology of Idiopathic Focal Dystonia. ACNR 2010, 10:14-18.
9. Jankovic J, Brin M. Therapeutic uses of botulinum toxin. N Engl J Med 1991, 324:1186-1194. 10.1056/NEJM199104253241707, 2011163.
10. Brashear A, Bergan K, Wojcieszek J, et al. Patients' perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A. Mov Disord 2000, 15:150-153. 10.1002/1531-8257(200001)15:1<150::AID-MDS1024>3.0.CO;2-X, 10634256.
11. Burgen ASV, Dickens F, Zatman LJ. The action of botulinum toxin on the neuromuscular junction. J Physiol 1994, 109:10-24.
12. Truong D, Duane DD, Jankovic J. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomised double-blind placebo-controlled study. Mov Disord 2005, 20:783-791. 10.1002/mds.20403, 15736159.
13. Costa J, Espirito-Santo C, Borges A, Ferreira JJ, Coelho M, Moore P, et al. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev 2005, 25(1):CD003633.
14. Delnooz C, Horstink MWIM, Tijssen MA. Warrenburg van der BPC: Paramedical Treatment in Primary Dystonia: A Systematic Review. Mov Disord 2009, 24:2187-2198. 10.1002/mds.22608, 19839012.
15. Tassoreli C, Mancini F, Balloni L, Pacchetti C, Sandrini G, Nappi G, et al. Botulinum toxin and neuromotor rehabilitation: an integrated approach to idiopathic cervical dystonia rehabilitation: an integrated approach to idiopathic cervical dystonia. Mov Disord 2006, 21:2240-2243. 10.1002/mds.21145, 17029278.
16. El-Bahrawy MN, El-Tamawy MS, Shalaby NM, Abdel-Alim AM. Cervical dystonia: Abnormal head posture and its relation to hand function. Egypt J Neurol, Psychiatr Neurosurg 2009, 46:203-208.
17. Queiroz MA, Chien HF, Sekeff-Sallem FA, Barbosa ER. Physical therapy program for cervical dystonia:a study of 20 cases. Funct Neurol 2012, 27:187-192.
18. Bleton J-P. Physiotherapy of focal dystonia: A physiotherapist's personal experience. Eur J Neurol 2010, 17(SUPPL 1):107-112.
19. Shumway-Cook A, Woollacott MH. Motor control, translating research into clinical practice 2010, Wolters Kluwer Lippincott Williams & Wilkins, 4.
20. Kleim JA, Jones TA. Principles of expierence dependent neural plasticity: Implications for rehabilitation after brain damage. J Speech Lang Hear Res 2008, 51:s225-s239. 10.1044/1092-4388(2008/018), 18230848.
21. AGREE next step consortium AGREE II. Appraisal of Guidelines for Research & Evaluation (AGREE) Instrument 2001, http://www.agreetrust.org, AGREE next step consortium.
22. Tijssen MAJ, Dool Van Den J, Hillten Van JJ, Warrenburg Van Der BPC. DystonieNet http://dystonienet.nl.
23. Consky ES, Lang AE. Clinical assessments of patients with cervical dystonia. Therapy with botulinum toxin 1994, pp. 211-37. New York: Marcel Dekker, Jankovic J, Hallett M.
24. Comella CL, Stebbins GT, Goetz CG, Chmura TA, Bressman SB, Lang AE. Teaching tape for the motor section of the Toronto Western Spasmodic Torticollis Scale. Mov Disord 1997, 12:570-575. 10.1002/mds.870120414, 9251076.
25. Jahanshahi M, Marsden CD. Body concept, disability and depression in patients with spasmodic torticollis. Behav Neurol 1990, 3:117-131.
26. Tsui JK, Stoessl AJ, Eisen E, Calne S. Double blind study of botulin toxin in spasmodic torticollis. Lancet 1986, 2(8501):245-246.
27. Guy W. Clinical global impression. ECDEU Assessment Manual for Psychopharmacology, revised 1976, 217-222. Rockville: MI: National Insitute of Mental Health, Guy W.
28. Zaider TI, Heimberg RG, Fresco DM, Schneier FR, Liebowitz MR. Evaluation of the clinical global impression scale among individuals with social anxiety disorder. Psychol Med 2003, 33:611-622. 10.1017/S0033291703007414, 12785463.
29. Capuano-Pucci D, Rheault W, Aukai J. Intratester and intertester reliability of the cervical range of motion device. Arch Phys Med Rehab 1991, 72:340.
30. Breivik EK, Bjornsson GA, Skovlund E. A comparison of pain rating scales by sampling from clinical trial data. Clin J Pain 2000, 16:22-28. 10.1097/00002508-200003000-00005, 10741815.
31. Lundeberg T, Lund I, Dahlin L, Borg E, Gustafsson C, Sanda L, et al. Reliability and responsiveness of three different pain assesments. In J Rehabil Med 2001, 33:279-283.
32. Muller J, Wissel J, Kemmler G, Voller B. Craniocervical dystonia questionnaire (CDQ-24):development and validation of a disease-specific quality of life instrument. J Neurol Neurosurg Psychiatry 2004, 75:749-753. 10.1136/jnnp.2003.013441, 1763554, 15090572.
33. Brazier JE, Harper R, Jones NMB, O'Cathain AThomas KJ, Usherwood T, Westlake L. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 1992, 305:160-164. 10.1136/bmj.305.6846.160, 1883187, 1285753.
34. Müller J, Kemmler G, Wissel J. The impact of blepharospasm and cervical dystonia on health-related quality of life and depression. J Neurol 2002, 249:842-846. 10.1007/s00415-002-0733-1, 12140667.
35. Beck TA, Epstein N, Brown G, Steer RA. An inventory to measure clinical anxiety: psychometric proportions. J Consult Clin Psychol 1988, 56:893-897.
36. Beck TA, Steer RA, Garbin MG. Psychometric proportions of the Beck Depression Inventory: twenty five years of evaluation. Clin Psychol Rev 1988, 8:77-100.
37. Fydrich T, Dowdall D, Chambless DL. Reliability and validity of the Beck Anxiety Inventory. J Anxiety Disord 1992, 6:55-61.
38. Bouwmans C, Hakkaart-van Roijen L, Koopmanschap M, Krol M, Severens H, Brouwer W. Productivity Cost Questionnaire 2013, Erasmus University Rotterdam: Institute for Medical Technology Assesment.
39. Hakkaart-van Roijen L, Tan SS, Bouwmans CAM. Handleiding voor kostenonderzoek: Methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg College voor zorgverzekeringen 2010, Erasmus University Rotterdam: Institute for Medical Technology Assessment.
40. EuroQoL WorkGroup EuroQol-a new facility for the measurement of healthrelated quality of life. Health Policy 1990, 16:199-208. EuroQoL WorkGroup.
41. Brans JWM, Lindeboom R, Aramideh M, Speelman JD. Longterm effects of botulinum toxin on impairment and functional health in cervical dystonia. Neurology 1998, 50:1461-1463. 10.1212/WNL.50.5.1461, 9596007.
42. Brans JW, Lindeboom R, Snoek JW, Zwarts MJ, van Weerden TW, Brunt ER, et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology 1996, 46:1066-1072. 10.1212/WNL.46.4.1066, 8780093.
43. de Morree JJ. Dynamiek van het menselijk bindweefsel: functie beschadiging en herstel 2001, Houten: Bohn Stafleu Van Loghum.
44. Fung YC. Biomechanics. Mechanical properties of living tissues 1993, New York: Springer Verlag.
45. Shea JB, Morgan RL. Contextual interference effects on the acquisition, retention and transfer of a motor skill. In J Exp Psychol 1979, 5:179-187.
46. Schmidt RA, Lee TD. Motor control and learning: a behavioral emphasis 2005, Champaign, IL: Human Kinetics.
47. Shea CH, Shebilske WL, Worchel S. Motor learning and control 1993, Englewood Cliffs, NJ: Prentice-Hall.
48. Fitts PM, Posner MI. Human performance 1967, Belmont CA: Brooks/Cole.